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Abstract
Factors leading to Cardiovascular Disease (CVD) in Autoimmune Rheumatic Diseases (ARD) include: a) atherosclerosis
and macro-microvascular coronary artery disease b) pericardial, myocardial and vascular inflammation c) heart valve
disease d) heart failure and e) pulmonary hypertension.
Cardiology utilizes various non-invasive imaging modalities, such as rest/stress Electrocardiogram (ECG),
echocardiography, nuclear imaging and more recently Cardiovascular Magnetic Resonance (CMR) to detect
ischemic or inflammatory disease in ARD. Exercise ECG is a reliable prognostic test for identification of
patients either very unlikely or very likely to have cardiac events. However, this is not the case for
intermediate risk patients. In stress echocardiography the diagnostic end point for the detection of myocardial
ischemia is the induction of a transient worsening in regional function during stress. It provides similar
diagnostic and prognostic accuracy as radionuclide stress perfusion, but at a lower cost and without radiation
exposure. Stress Myocardial Perfusion Scintigraphy (MPS) is a non-invasive imaging modality for patients with
suspected coronary artery disease, but has important limitations including radiation exposure, imaging
artefacts and low spatial resolution, which preclude detection of small myocardial scars commonly found in
ARD. By identifying early stages of inflammation and perfusion defects, CMR can shed light on the exact
pathophysiologic background of myocardial lesions, even if the underlying ARD seems stable. However, high
cost and lack of availability and expertise limit wider adoption.
Hopefully, CMR will not have the same fate as Oedipous, who despite answering the Sphinx’s riddle
successfully, finally came to a bitter end; for in the case of CMR overcoming fate is, in fact, in our hands.
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Background
In Greek mythology, the Sphinx was a monster with the
head of a woman, the wings of a griffin and the body of
a lion. The Sphinx stopped travellers on the road to the
city of Thebes and asked them a riddle. If they answered
wrong they were killed by the Sphinx. Cardiovascular
Disease (CVD) is the Sphinx of our times in the man-
agement of Autoimmune Rheumatic Diseases (ARD)
and the riddle, for which we also seem to lack the an-
swer, is a complex cardiovascular pathophysiology. The
systemic manifestations of ARD attract most of the at-
tention of attending rheumatologists, while cardiologists
are mostly unaware of CVD in ARD. Lack of diagnostic
algorithms for early assessment of ARD, when CVD is
still silent only compounds these issues [1]. Further-
more, although use of targeted treatment in ARD has
led to a reduction of disease-associated mortality, in-
creased CVD incidence lowers life expectancy compared
to the general population [2–7].
The clinical scenarios leading to increased CVD in
ARD include:
a) Atherosclerosis and macro-microvascular Coronary
Artery Disease (CAD). These are the commonest
suspects causing increased CVD and mortality in
ARD [8]. Rheumatoid Arthritis (RA) has a 1.5- to
2.0-fold risk of CAD, compared with controls, even
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before the diagnosis of arthritis [9–11]. Traditional
risk assessment usually underestimates CVD risk
in ARD [12, 13]. Furthermore, inflammation and
autoimmunity, the main characteristics of ARD,
promote the development of atherosclerosis [14, 15].
RA, spondyloarthropathies, Systemic Lupus
Erythematosus (SLE), Antiphospholipid Syndrome
(APS) and systemic vasculitides have all been
associated with accelerated atherosclerosis [16–20, 38].
Notably, CAD risk in RA is similar to that of diabetes
mellitus and the associated atherosclerotic plaques are
more susceptible to instability and rupture, with higher
re-infraction rates and worse prognosis [21–23].
Although SLE presents with less “inflammatory
reaction” compared with RA and/or
spondyloarthropathies, it is characterized by
higher incidence of CVD. Atherosclerosis in SLE
is associated with older age at diagnosis and
longer disease duration, supporting the hypothesis
that chronic exposure to SLE immune dysregulation
promotes CVD [24]. Early damage of both macro-
and microvasculature occurs before or shortly after
SLE diagnosis [25, 26]. Macro-or microvascular CAD
is also common in SLE, with 54 % of patients having
non-calcified coronary plaques and impaired coronary
flow reserve, even in patients with seemingly normal
coronary arteries [27, 28]. These findings are well
correlated with disease activity and disease duration
[27, 29–33]. Finally, High Density Lipoprotein (HDL) is
decreased in SLE, while Low Density Lipoprotein
(LDL), Very Low Density Lipoprotein (VLDL),
proinflammatory HDL and triglyceride levels are
increased [34, 35]. Therefore, early treatment of
immune dysregulation is imperative for CAD
prevention.
b) Pericardial, Myocardial and Vascular inflammation.
Inflammatory heart disease, despite being considered
a rare complication of ARD, can significantly
contribute to increases in CVD mortality. The
typical appearance of myopericarditis is more
common in SLE, but also has notable impact in
CVD morbidity of other ARDs, such as RA, mixed
collagen diseases, systemic sclerosis, vasculitis,
sarcoidosis and inflammatory myopathies [35]. Overt
clinical presentation of myopericarditis is typically
found only in a minority of SLE patients. In the
majority of ARD patients, however, myopericarditis
remains silent, leading to delays in diagnosis which
in turn can cause deterioration into Heart Failure
(HF) and arrhythmias [36].
Additionally, inflammation of large-, medium- and
small-sized blood vessel walls, either due to primary
or secondary ARD, may lead to stroke, myocardial
infarction, visual abnormalities, limb/jaw claudication
and digital ulcers [37]. Myocardial vasculitis is
common in medium/small vessel vasculitis and in
APS; it may cause myocardial ischemia due to
involvement of epicardial coronary arteries, or
small intramural cardiac vessels, finally leading to
Left Ventricular (LV) impairment [38, 39].
c) Heart Valve Disease (HVD). HVD is the commonest
cardiac disease in APS, with a prevalence of 30 %.
Diagnosis is based on the presence of valvular
thickening or vegetations (mainly mitral and aortic)
as described by Libman and Sacks for patients with
SLE [40]. The coexistence of Antiphospholipid
Antibodies (aPL) with SLE carries a 3-fold greater
risk of HVD and confirms that the involvement
of these antibodies in the pathophysiologic
mechanism leads to valve thrombosis secondary
to hypercoagulability [41]. Progressive valve disease
has also been identified in RA [42, 43]. Transthoracic
and/or Transoesophageal Echocardiography (TTE
and TEE, respectively) are currently the cornerstone
of early and accurate diagnosis [41].
d) Heart Failure (HF). HF in ARD can be caused by
ischemic or non-ischemic heart disease and
contributes to increased mortality [44]. In RA, the
prevalence of HF is 2-fold higher than in general
population and remains increased after adjusting for
classic CVD risk factors and ischemic heart disease
[45, 46]. HF is also seen in SLE, inflammatory
myopathies, systemic sclerosis, ankylosing spondylitis
and vasculitis, as the endpoint of myocardial
inflammation [47–50].
Fibrotic cardiomyopathy, highly prevalent in systemic
sclerosis, vasculitis, myositis and sarcoidosis, may also
lead to impaired LV function [51]. However, LV
systolic function remains normal until the late stages
of the disease and only imaging techniques such as
Tissue Doppler and Cardiovascular Magnetic
Resonance (CMR) can identify these lesions at a
preclinical stage [52, 53].
e) Pulmonary Arterial Hypertension (PAH). PAH
affects 0.5-15 % of ARD and carries worse prognosis
compared with idiopathic PAH. It is most common
in systemic sclerosis and is responsible for 30 % of
disease-related deaths [54]. Microangiopathy and
chronic hypoxemia secondary to interstitial lung
fibrosis are the major causes of PAH in SSc [55].
LV dysfunction and thromboembolic disease are
additional causes of PAH in ARD and are due to
APS and primary Sjogren syndrome respectively
[56, 57]. Despite the use of new imaging modalities,
more than 50 % of PAH in ARD is missed, and is
diagnosed only when the disease is in advanced stages
[58]. A schematic expression of various clinical
scenarios of CVD in ARD was presented in Table 1.
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Cardiovascular diagnosis in the era of
multimodality imaging
Cardiology uses various non-invasive imaging modalities,
such as rest/stress Electrocardiogram (ECG), echocardi-
ography, nuclear techniques and more recently CMR, to
detect ischemic or inflammatory disease in ARD. Exer-
cise ECG (ExECG) is a reliable prognostic test for identi-
fication of patients who are either very unlikely or very
likely to have cardiac events. However, this is not the
case for intermediate risk patients or patients with small
vessel vasculitis, who may be missed both by routine
non-invasive as well as invasive assessment [59]. ECGs
can be indicative of myocarditis, and there is an associ-
ation between transmural LV myocardial oedema de-
tected by CMR and T wave inversion in clinically
suspected acute myocarditis. However, this is an expres-
sion of reversible myocardial oedema during the acute
disease phase and can not be used as a predictor of LV
systolic dysfunction during follow-up [60].
Echocardiography is the cornerstone imaging tech-
nique to assess cardiac morphology in everyday practice.
The addition of new techniques, such as speckle tracking
echocardiography and in particular longitudinal deform-
ation, has been successfully used for the assessment of
subclinical LV dysfunction and monitoring of the effects
of anakinra, an interleukin-1 receptor antagonistant, in
treatment on LV function in ARD patients, particularly
when CAD coexists [61–64].
Stress echocardiography is defined as a combination of
2D echocardiography either with a physical or pharma-
cological stress. The diagnostic end point for the detec-
tion of myocardial ischemia is the induction of a
transient worsening in regional function during stress. It
has similar diagnostic and prognostic accuracy as radio-
nuclide stress perfusion tests, but at a lower cost, with-
out environmental impact and with no biohazards for
patients and physicians. Additionally, the assessment of
coronary flow reserve by Doppler echocardiography can
reveal microvascular disease in ARD [65] and also sub-
clinical coronary artery disease [66]. Despite being an
operator dependent technique, unable to perform tissue
characterisation, echocardiography is the most cost-
effective approach for the non-invasive exclusion and/or
evaluation of the CAD possibility [67].
Stress Myocardial Perfusion Scintigraphy (MPS) is a
non-invasive imaging modality used in patients with sus-
pected CAD, commonly found in RA and SLE [68].
However, MPS has serious limitations including radi-
ation exposure, imaging artefacts and low spatial reso-
lution, which do not permit detection of subendocardial
ischemia and small scars seen in ARD [69]. The CE-
MARC study currently supports wider adoption of CMR
for CAD assessment, owing to concerns regarding car-
cinogenesis risks associated with medical use of ionising
radiation [70]. In a study comparing of Single Photon
Emission Tomography (SPECT), Positron Emission
Tomography (PET), and CMR, all techniques were
shown to have high sensitivity, with a broad range for
specificity observed in CMR [71].
Conclusions
To correlate Greek mythology with more contemporary
terms, CMR now takes the place of Oedipus in our para-
digm. Like its “predecessor”, CMR is capable of success-
fully answering the riddle of CVD in ARD, by increasing
our diagnostic capabilities and detecting cardiac path-
ology before any change in systolic or diastolic indexes
takes place [1]. Additionally, by identifying early stages
of inflammation and perfusion defects, CMR can shed
light on the exact pathophysiologic background of myo-
cardial lesions even if the underlying ARD appears
stable. It also provides the additive value of being able to
assess myocardial status independently of systemic in-
flammatory processes, leading to individualization of
cardiac treatment, irrespective of ARD status [1]. Finally,
stress perfusion CMR allows for early detection of
microvascular disease, a common finding in ARD, com-
monly missed by nuclear imaging techniques due to
their low spatial resolution [69].
Unfortunately, lack of availability and expertise,
insufficient collaboration between cardiologists and radi-
ologists, unfamiliarity of rheumatologists with the ad-
vantages of CMR in ARD and significant associated
costs, especially when a stress study is added, are serious
obstacles preventing more widespread adoption of CMR
in ARD monitoring. Hopefully, this excellent diagnostic
tool will not have the same fate as Oedipous, who des-
pite successfully answering the Sphinx’s riddle, finally
Table 1 Clinical scenarios of CVD in ARD
Clinical scenarios Coronary artery disease Micro-vascular disease Myocarditis/Pericarditis/Vasculitis PAH HF Valve disease
Typical chest pain ++++ ++ +++ + + +
Atypical chest pain ++ +++++ +++ ++ ++ +
Shortness of breath ++ +++ ++++ ++++++ ++++ ++++
Syncope + ++ ++ ++++ +++ ++++
Arrhythmia ++ ++ +++ ++ ++++ ++++
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came to a bitter end; for in the case of CMR, overcom-
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